Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bipolar disorder
Biotech
Rapport's ph. 2 bipolar mania win impresses analysts
The phase 2 bipolar mania study has hit its primary endpoint, furthering the biotech’s efforts to make RAP-219 a multi-indication blockbuster.
Nick Paul Taylor
Oct 20, 2026 9:19am
Teva saddles up as bidder for bankrupt BioXcel’s CNS assets
Aug 28, 2026 9:17am
Autobahn races toward ph. 3 after midstage bipolar depression win
Jun 4, 2026 11:31am
Biohaven's biopolar med fails pivotal test
Mar 3, 2025 5:14pm
J&J jettisons several programs, including ph. 2 Alzheimer's work
Oct 15, 2024 2:00pm
Bipolar research initiative announces $36M in new funding
Sep 30, 2024 1:13pm
